Shanghai Pharmaceuticals Holding's subsidiary company Luosashita Capsules has been approved for production.
Shanghai Pharmaceuticals (601607.SH) announced recently that its subsidiary, Shanghai Pharmaceuticals Group Qingdao Guofeng Pharmaceutical Co., Ltd., has received the "Drug Registration Certificate" issued by the National Medical Products Administration for Rosusan Capsules, a new type of oral small molecule hypoxia inducible factor prolyl hydroxylase inhibitor. This drug is approved for production and is suitable for treating anemia caused by chronic kidney disease (CKD), including both dialysis and non-dialysis patients.
Shanghai Pharmaceuticals Holding (601607.SH) announced that its subsidiary, Shanghai Pharmaceuticals Holding Group Qingdao Guofeng Pharmaceutical Co., Ltd., has received a Drug Registration Certificate from the National Medical Products Administration for its Roxadustat Capsules. The drug has been approved for production. Roxadustat is a novel oral small molecule hypoxia-inducible factor prolyl hydroxylase inhibitor, used for the treatment of anemia caused by chronic kidney disease (CKD) in both dialysis and non-dialysis patients.
Related Articles
SpaceX and Charter are in talks to collaborate on mobile phone services, with the satellite giant accelerating its entry into the consumer-level communication market.
Apple Inc. (AAPL.US) suffers another major loss: Vision Pro executive joins OpenAI, escalating the competition for talent in the AI field.
.png)
HK Bull/Bear Outstanding Qty Ratio(55:45) | June 27th
SpaceX and Charter are in talks to collaborate on mobile phone services, with the satellite giant accelerating its entry into the consumer-level communication market.
Apple Inc. (AAPL.US) suffers another major loss: Vision Pro executive joins OpenAI, escalating the competition for talent in the AI field.
HK Bull/Bear Outstanding Qty Ratio(55:45) | June 27th
RECOMMEND
